{"url_path":"/sec/bdtx/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","accession_number":"0001104659-26-065254","cik":"0001701541","ticker":"BDTX","issuer_name":"Black Diamond Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","primary_entity_key":"0001701541","primary_entity_name":"Black Diamond Therapeutics, Inc."},"word_count":320,"has_tables":true,"body_markdown":"false\n0001701541\n\n0001701541\n\n2026-05-21\n2026-05-21\n\n0001701541\n\ndei:FormerAddressMember\n\n2026-05-21\n2026-05-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C.\n20549**\n\n** **\n\n \n\n**FORM 8-K**\n\n** **\n\n \n\n**CURRENT REPORT**\n\n**Pursuant\nto Section 13 or 15(d)\nof the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nMay 21, 2026** \n\n \n\n \n\n**BLACK DIAMOND THERAPEUTICS, INC.**\n\n**(Exact name\nof registrant as specified in its charter)**\n\n \n\n \n\n**Delaware**\n**001-39200**\n**81-4254660**\n\n**(State or other jurisdiction**\n**(Commission**\n**(I.R.S. Employer**\n\n**of incorporation)**\n**File Number)**\n**Identification No.)**\n\n \n\n**245 First Street, 18th Floor**\n\n**Cambridge, MA 02142**\n\n**(Address of principal\nexecutive offices, including zip code)**\n\n \n\n**(617) 252-0848**\n\n**(Registrant’s telephone number, including\narea code)**\n\n \n\n**One Main Street, 14th Floor**\n\n**Cambridge****,\nMA****02142**\n\n**(Former Name or Former Address, if Changed Since Last Report)** ** **  \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act: \n\n \n\nTitle\nof each class\nTrading\n\nSymbol(s)\nName\nof each exchange on which registered\n\nCommon Stock, $0.0001 par value per share\nBDTX\nThe Nasdaq Global Select Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}